Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06126315Phase 2Recruiting

Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS

Role: collaborator

NCT04894240Phase 1Completed

A Study of Monepantel in Individuals With Motor Neurone Disease

Role: collaborator

NCT04788745Phase 2Completed

Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

Role: collaborator

NCT05136222Not ApplicableRecruiting

Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease

Role: collaborator

All 4 trials loaded